Comparing new CDK4/6 drugs for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a newer targeted therapy (dalpiciclib) causes fewer side effects than two similar drugs (abemaciclib and ribociclib) in people with early-stage, hormone receptor-positive, HER2-negative breast cancer after surgery. The goal is to find a better-tolerated treatment to reduce the risk of cancer returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older with stage II or III breast cancer at diagnosis.
- Your breast cancer must be hormone receptor-positive and HER2-negative, confirmed by a pathology report.
- You must have had surgery to remove all cancer, with clear margins, and be considered high risk for recurrence (for example, at least 4 positive lymph nodes).
- You cannot have cancer that has spread to other parts of the body or come back in the same area.
- You must not have had any other cancer in the last 5 years (except for certain minor skin or cervical cancers).
- You must be in good enough general health to undergo treatment (good blood counts, kidney and liver function, and no active infections or major heart problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial tests a combination of a new immunotherapy drug (adebrelimab) with a targeted pill (dalpiciclib) and standard hormone therapy for women with advanced hormone receptor positive, HER2 negative breast cancer. It may help patients who have not yet had certain prior treatments, aiming to slow the cancer's growth.
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.